RU2012157597A - Rhamm-связывающие пептиды - Google Patents

Rhamm-связывающие пептиды Download PDF

Info

Publication number
RU2012157597A
RU2012157597A RU2012157597/04A RU2012157597A RU2012157597A RU 2012157597 A RU2012157597 A RU 2012157597A RU 2012157597/04 A RU2012157597/04 A RU 2012157597/04A RU 2012157597 A RU2012157597 A RU 2012157597A RU 2012157597 A RU2012157597 A RU 2012157597A
Authority
RU
Russia
Prior art keywords
rhamm
seq
cells
binding
binding peptides
Prior art date
Application number
RU2012157597/04A
Other languages
English (en)
Russian (ru)
Inventor
Леонард Г. ЛЮИТ
Ева А. ТАРЛИ
Кеннет Виржил ЭСГУЭРРА
Original Assignee
Лондон Хелс Сайенсис Сентр Рисерч Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Лондон Хелс Сайенсис Сентр Рисерч Инк. filed Critical Лондон Хелс Сайенсис Сентр Рисерч Инк.
Publication of RU2012157597A publication Critical patent/RU2012157597A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043—Fluorescein, used in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01T—MEASUREMENT OF NUCLEAR OR X-RADIATION
    • G01T1/00—Measuring X-radiation, gamma radiation, corpuscular radiation, or cosmic radiation
    • G01T1/16—Measuring radiation intensity
    • G01T1/24—Measuring radiation intensity with semiconductor detectors
    • G01T1/249—Measuring radiation intensity with semiconductor detectors specially adapted for use in SPECT or PET
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Optics & Photonics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • High Energy & Nuclear Physics (AREA)
RU2012157597/04A 2010-05-31 2011-05-31 Rhamm-связывающие пептиды RU2012157597A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34997010P 2010-05-31 2010-05-31
US61/349,970 2010-05-31
PCT/CA2011/000613 WO2011150495A1 (en) 2010-05-31 2011-05-31 Rhamm binding peptides

Publications (1)

Publication Number Publication Date
RU2012157597A true RU2012157597A (ru) 2014-07-20

Family

ID=45066087

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2012157597/04A RU2012157597A (ru) 2010-05-31 2011-05-31 Rhamm-связывающие пептиды

Country Status (9)

Country Link
US (2) US9090659B2 (https=)
EP (2) EP2576597A4 (https=)
JP (1) JP6153467B2 (https=)
KR (1) KR101947529B1 (https=)
CN (2) CN103038248B (https=)
AU (1) AU2011261107B2 (https=)
CA (1) CA2801237A1 (https=)
RU (1) RU2012157597A (https=)
WO (1) WO2011150495A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014082042A2 (en) 2012-11-25 2014-05-30 The Regents Of The University Of California Peptides that stimulate subcutaneous adipogenesis
US10844102B2 (en) 2014-05-28 2020-11-24 The Regents Of The University Of California Peptides, compositions, and methods for stimulating subcutaneous adipogenesis
US10562935B2 (en) 2015-03-20 2020-02-18 London Health Sciences Centre Research Inc. Stapled peptides and uses thereof
US11572384B2 (en) * 2016-04-28 2023-02-07 Forschungsverbund Berlin E.V. Unusual substrates of tubulin tyrosine ligase
KR102524369B1 (ko) * 2020-08-14 2023-04-20 연세대학교 산학협력단 플루오레세인에 결합하는 펩타이드, 이를 암호화하는 핵산 분자, 단백질 발현 벡터, 이를 이용한 바이오 진단 프로브 및 바이오 진단 키트

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4714681A (en) 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US4713325A (en) 1983-06-14 1987-12-15 The Regents Of The University Of California Hybridomas producing monoclonal antibodies specific for FeLV p27
US4716117A (en) 1984-10-26 1987-12-29 Chiron Corporation Monoclonal antibodies to factor VIIIC
CA1207852A (en) 1984-02-29 1986-07-15 William D. Cornish Non-resonant microwave frequency halver
US4762915A (en) 1985-01-18 1988-08-09 Liposome Technology, Inc. Protein-liposome conjugates
US4720459A (en) 1985-02-14 1988-01-19 Medical College Of Wisconsin Research Foundation, Inc. Myelomas for producing human/human hybridomas
GB9207949D0 (en) 1992-04-09 1992-05-27 Univ Manitoba Molecular cloning of a novel hyaluronan receptor that mediates tumor cell motility
US5824315A (en) 1993-10-25 1998-10-20 Anergen, Inc. Binding affinity of antigenic peptides for MHC molecules
GB9420740D0 (en) 1994-10-14 1994-11-30 Univ Manitoba Sequence of the hyaluronan receptor gene
CA2166155C (en) 1995-12-27 2008-02-05 Eva Anne Turley Agents binding to hyaluronic acid binding domains and the use thereof
GB9607441D0 (en) 1996-04-10 1996-06-12 Univ Manitoba Human hyaluronan receptor
IL120561A0 (en) 1996-04-24 1997-07-13 Akzo Nobel Nv Peptides suitable for use in immunosuppressive therapy
CA2237051A1 (en) 1997-12-19 1999-06-19 Eva A. Turley Enhanced affinity hyaluronan binding peptides
JP2002530066A (ja) 1998-11-19 2002-09-17 スミスクライン・ビーチャム・コーポレイション Ｒｈａｍｍアンタゴニスト抗体
US6911429B2 (en) 1999-04-01 2005-06-28 Transition Therapeutics Inc. Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
US6864235B1 (en) 1999-04-01 2005-03-08 Eva A. Turley Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
US20030050236A1 (en) * 2000-08-15 2003-03-13 The University Of Chicago Compounds that enhance tumor death
JP4210746B2 (ja) * 2003-05-12 2009-01-21 独立行政法人農業生物資源研究所 葯特異的遺伝子および該遺伝子のプロモーター、並びにそれらの利用
NZ551775A (en) 2004-06-01 2010-12-24 Univ Virginia Dual small molecule inhibitors of cancer and angiogenesis
US20060148014A1 (en) 2004-12-09 2006-07-06 Sergei Agoulnik Tubulin isotype screening in cancer therapy using hemiasterlin analogs
EP1831697A4 (en) 2004-12-09 2011-01-26 Eisai R&D Man Co Ltd SEARCH FOR TUBULINISOTYPES IN CANCER THERAPY USING HALICHONDRIN B ANALOG
WO2006086111A2 (en) 2005-02-10 2006-08-17 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
WO2007046796A1 (en) * 2005-10-19 2007-04-26 Creighton University Peptides and methods of use
US8715653B2 (en) * 2006-11-21 2014-05-06 The Regents Of The University Of California Modulation of Rhamm (CD168) for selective adipose tissue development
US20100062000A1 (en) 2006-11-21 2010-03-11 The Regents Of The University Of California Rhamm, a Co-Receptor and Its Interactions with Other Receptors in Cancer Cell Motility and the Identification of Cancer Prognitor Cell Populations
WO2008138916A1 (en) 2007-05-10 2008-11-20 Pronota N.V. Isolation of peptides and proteomics platform
EP2207810A4 (en) 2007-10-12 2011-12-07 London Health Sciences Ct Res Inc COMPOSITIONS WHICH INFLUENCE THE HYALURONIC ACID-ACTIVITY
US20090220991A1 (en) 2008-02-29 2009-09-03 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
WO2010115141A2 (en) * 2009-04-02 2010-10-07 New York University System and uses for generating databases of protein secondary structures involved in inter-chain protein interactions
US20130157285A1 (en) 2011-10-12 2013-06-20 The Regents Of The University Of California Identification of invasive and slow-growing tumorigenic cell subsets in tumors

Also Published As

Publication number Publication date
JP2013534814A (ja) 2013-09-09
CN103038248A (zh) 2013-04-10
KR101947529B1 (ko) 2019-02-13
CN103038248B (zh) 2016-08-10
EP2576597A4 (en) 2013-11-06
EP3168226A3 (en) 2017-07-26
CN106188270A (zh) 2016-12-07
WO2011150495A1 (en) 2011-12-08
US9090659B2 (en) 2015-07-28
KR20130126455A (ko) 2013-11-20
US9890197B2 (en) 2018-02-13
US20130157338A1 (en) 2013-06-20
JP6153467B2 (ja) 2017-06-28
US20160031942A1 (en) 2016-02-04
EP2576597A1 (en) 2013-04-10
EP3168226A2 (en) 2017-05-17
CA2801237A1 (en) 2011-12-08
AU2011261107B2 (en) 2016-04-14
AU2011261107A1 (en) 2013-01-17

Similar Documents

Publication Publication Date Title
Chen et al. Sublethal heat stress-induced O-GlcNAcylation coordinates the Warburg effect to promote hepatocellular carcinoma recurrence and metastasis after thermal ablation
Klomp et al. Epigenetic regulation of somatostatin and somatostatin receptors in neuroendocrine tumors and other types of cancer
RU2012157597A (ru) Rhamm-связывающие пептиды
Timmers et al. Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma
Kam et al. Detection of a long non-coding RNA (CCAT1) in living cells and human adenocarcinoma of colon tissues using FIT–PNA molecular beacons
ES2583754T3 (es) Productos génicos expresados de manera diferencial en tumores y utilización de los mismos
TWI715332B (zh) 包括胃腸癌和胃癌的幾種腫瘤的新型免疫療法
ES2883335T3 (es) Métodos y composiciones para el diagnóstico y tratamiento del glioblastoma
Boufaied et al. Obesogenic high-fat diet and MYC cooperate to promote lactate accumulation and tumor microenvironment remodeling in prostate cancer
JP2019524840A (ja) 抗腫瘍薬の調製におけるｖｃｐ阻害剤及び腫瘍溶解性ウイルスの使用
HRP20231525T1 (hr) Postupci i pripravci za dijagnozu i liječenje raka
JP2015530081A5 (https=)
US10391159B2 (en) Methods and materials for treating cancer
RU2016138428A (ru) Пептиды neil3 и включающие их вакцины
US20170080065A1 (en) Methods and materials for treating cancer
JP2013534814A5 (https=)
Li et al. Preclinical study of an 18F-labeled glutamine derivative for cancer imaging
WO2013148984A1 (en) Dual function markers for diagnostics and therapeutics for upper gastrointestinal tract precancer
Giles et al. The rate of operative success achieved with radioguided occult lesion localization and intraoperative ultrasonography in patients with recurrent papillary thyroid cancer
Zhang et al. MAGED4 expression in glioma and upregulation in glioma cell lines with 5-aza-2'-deoxycytidine treatment
Koustoulidou et al. Cancer-associated fibroblasts as players in cancer development and progression and their role in targeted radionuclide imaging and therapy. Cancers (Basel). 2021; 13: 1100
Pagou et al. Can gallium-68 compounds partly replace (18) F-FDG in PET molecular imaging
Kawakami et al. Dendritic cell based personalized immunotherapy based on cancer antigen research
EP4470560A1 (en) Tumor immunotherapy
Guan et al. 995P A pan-cancer analysis of KMT2D as a potential biomarker for immune checkpoint therapy

Legal Events

Date Code Title Description
FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20140602